Hosted on MSN1mon
Cipla set to bring Afrezza, 1st inhalable insulin since Exubera, to Indian markets by 2025Mumbai-based pharmaceutical giant Cipla will distribute and market the drug in India. Inhaled from the mouth at the beginning of a meal, Afrezza dissolves rapidly into the lungs and delivers ...
Novartis and Cipla signed a perpetual licence agreement for the diabetes drug Galvus. Credit: Novartis AG. India-based pharmaceutical company Cipla has entered into a perpetual licence agreement with ...
Shares of Cipla gained nearly 2 per cent on Monday, following the United States Food and Drug Administration (USFDA) classifying its Goa facility as “Voluntary Action Indicated” (VAI ...
Drug maker Cipla on Wednesday said it has received approval from the Central Drugs Standard Control Organisation for the distribution and marketing of Afrezza inhalation powder in India. Afrezza, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results